Harmane

Harmane (1-methyl-9H-pyrido[3,4-b]indole; CAS 486-84-0), also designated harman in the older literature, is the simplest methylated beta-carboline alkaloid, a heterocyclic indole derivative formed endogenously in mammalian tissues through the Pictet-Spengler condensation of tryptamine with acetaldehyde and found exogenously at quantifiable concentrations in brewed coffee, tobacco smoke, cooked and grilled meats, fermented sauces, and multiple plant species including Peganum harmala and Coffea arabica. The compound is a potent reversible inhibitor of monoamine oxidase A (MAO-A; IC50 approximately 60 nM in rat brain mitochondrial preparations, with 80- to 100-fold selectivity over MAO-B), a high-affinity ligand at the imidazoline I1 binding site (IC50 approximately 30 nM, with approximately 1000-fold selectivity over alpha-2 adrenergic receptors), and an inverse agonist at the benzodiazepine binding site of the gamma-aminobutyric acid type A (GABA-A) receptor (IC50 approximately 7 to 12 micromolar). Additional lower-affinity interactions include binding at serotonin 5-HT2B receptors (Ki approximately 267 nM), 5-HT2C receptors (Ki approximately 1135 nM), opioid receptors (IC50 approximately 2.8 micromolar), muscarinic acetylcholine receptors (IC50 approximately 24 micromolar), and weak inhibition of dopamine reuptake at the dopamine transporter (IC50 approximately 1490 nM).

The principal research and public health significance of harmane derives from its established association with essential tremor (ET), one of the most prevalent neurological movement disorders worldwide. The Louis laboratory at Columbia University demonstrated in two independent New York cohorts (total n = 285 ET cases, 286 controls) that blood harmane concentrations are approximately 50 percent higher in ET patients than in age- and sex-matched controls (adjusted odds ratio 1.56, 95% confidence interval 1.01 to 2.42), with familial ET cases showing the highest concentrations. Administration of harmane and related beta-carbolines to laboratory rodents produces a postural and action tremor that resembles ET in clinical features and drug-response characteristics, with the underlying neurocircuitry involving inferior olivary excitation, climbing fiber overactivation of cerebellar Purkinje cells, and progressive Purkinje cell loss. The metabolic hypothesis, proposed by Louis and Zheng (2010), suggests that the elevated harmane in ET may reflect a hereditarily reduced capacity to metabolize harmane to harmine through hepatic CYP2A6-mediated 7-hydroxylation, rather than increased dietary intake alone.

Pharmacokinetics in Sprague-Dawley rats are characterized by rapid absorption (Tmax approximately 20 minutes after oral dosing), low absolute oral bioavailability (approximately 19 percent), a short terminal elimination half-life (approximately 25 to 29 minutes), and moderate volume of distribution (1.6 L/kg). The principal metabolic pathway is hepatic cytochrome P450-mediated 7-hydroxylation (CYP2A family) yielding 7-hydroxy-harmane, which is subsequently O-methylated to produce harmine. Additional metabolic transformations include monohydroxylation at other ring positions, N-oxidation, dihydroxylation, and phase II conjugation (glucuronidation, sulfation, glutathione conjugation). Approximately 13 percent of an oral harmane dose is converted to harmine in rats, indicating meaningful biotransformation to a pharmacologically active metabolite with distinct DYRK1A kinase inhibitory activity.

Beyond the essential tremor association, harmane has been characterized as a DNA intercalating agent with cytotoxic and antimicrobial activity, an inhibitor of topoisomerase I and II, and a compound with antiparasitic activity against Leishmania infantum and the malaria parasite Plasmodium falciparum. The compound is endogenous to the human central nervous system, has been detected in human platelets, plasma, and cerebrospinal fluid, and crosses the blood-brain barrier. This monograph reviews the chemistry, natural occurrence, and endogenous formation of harmane; the multi-target receptor pharmacology; the comprehensive pharmacokinetic record; the preclinical neurotoxicity and tremor pharmacology; the clinical epidemiological evidence linking harmane to essential tremor; sourcing and quality verification for laboratory applications; reconstitution and handling; stack-interaction considerations for research with concurrent pharmacological agents; adverse-event and safety signal; and a structured comparative assessment of five beta-carboline alkaloids (harmine, harmaline, norharmane, norharmine, and tetrahydroharmane) against harmane on five competency standards.